Next generation of antimicrobials must be antibiofilms

Paul Michalet

 

Paul Michalet

CFO – ESC Montpellier business school

 
 

At BioFilm Pharma, Paul acts as Chief Finance, Strategy & Business Officer.

Paul has held a number of senior executive positions in the last 25 years. He had various responsibilities in finance for 10 years in manufacturing and service industries and, in the past 15 years, he held senior executive positions in biotechnology companies active in the chemical and cosmetics industries.

He was most recently CEO of IDD biotech, a drugg discovery company developping monoclonal antibodie which signed a 1rst structuring deal with Genmab.

Before this he was CFO and CBO in charge of the strategy and the business development of Fermentalg, an industrial biotech company listed in Compartment C of Eurolist Paris.

During his various senior positions, Paul negotiated several important license agreements and he achieved cumulative fund raising of over EUR200m, including 3 successful IPOs: Fermentalg in 2014, METabolicEXplorer in 2007 and Coletica in 2000 (today BASF Beauty Care Solutions)

Graduated from Montpelier business school and Certified European Financial Analyst, Paul Michalet is a member of the DFCG (France’s Finance Executives association) and the SFAF (France Society of Financial Analysts) and sits as an independent Director at the supervisory board of Biofilm Control and BioFilm Pharma.

Paul has led a number of various other executive positions in biotech companies, active in the chemical and cosmetic industry, in the last 25 years. He negotiated several important licenses agreements and he achieved cumulative fund raising of over EUR200M, including 3 successful IPOs: Fermentalg in 2014, METabolicEXplorer in 2007 and Coletica in 2000 (today BASF Beauty Care Solutions).